Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A strain of Lactobacillus rhamnosus ccfm1131 that relieves hyperuricemia

A technology of CCFM1131 and Lactobacillus rhamnosus, applied in the field of microbiology, can solve problems such as undiscovered, and achieve the effects of promoting expression, reducing serum uric acid levels, and reducing gout

Active Publication Date: 2022-08-09
无锡特殊食品与营养健康研究院有限公司
View PDF14 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The excretion of uric acid in the human body is mainly through the excretion of the kidneys and intestines. As a uric acid transporter, ABCG2 plays an important role in the intestinal excretion of uric acid. The expression of intestinal ABCG2 is considered to be a new target for the treatment of hyperuricemia and gout. point, but currently no drugs targeting intestinal ABCG2 have been found

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A strain of Lactobacillus rhamnosus ccfm1131 that relieves hyperuricemia
  • A strain of Lactobacillus rhamnosus ccfm1131 that relieves hyperuricemia
  • A strain of Lactobacillus rhamnosus ccfm1131 that relieves hyperuricemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Example 1: Screening of Lactobacillus rhamnosus CCFM1131

[0047] (1) Isolation and screening of Lactobacillus

[0048] (1) Take 1g of fresh feces from healthy adults. After gradient dilution, it was coated on LBS medium supplemented with 1% nystatin, and cultured in a constant temperature incubator at 37°C for 48h.

[0049] (2) After culturing, according to the color, size, edge shape, etc. of the colony, pick the colony with an inoculation loop and purify it by streaking.

[0050] (3) The obtained colonies were subjected to Gram staining and catalase analysis.

[0051] (4) Retain Gram-positive bacilli and catalase-negative bacteria.

[0052] (2) Molecular biological identification of Lactobacillus

[0053] (1) Single bacterial genome extraction

[0054] (A) the Lactobacillus obtained by step (1) is cultivated overnight;

[0055] (B) get 1mL of bacterial suspension cultured overnight in a 1.5mL centrifuge tube, centrifuge at 10000r / min for 2min, discard the super...

Embodiment 2

[0071] Example 2: Lactobacillus rhamnosus CCFM1131 has good tolerance to simulated gastrointestinal fluid

[0072] The cryopreserved Lactobacillus rhamnosus CCFM1131 was inoculated into the MRS medium, cultured at a temperature of 37°C for 14 hours, and then subcultured in the MRS medium for 2 to 3 times.

[0073] Take 3 mL of Lactobacillus rhamnosus CCFM1131 culture solution by centrifugation at 8000 × g for 2 min to collect bacterial cells, mix with 3 mL of pH 3.0 artificial simulated gastric juice (containing 3 g / L pepsin, pH=3.0 normal saline), and incubate at 37 °C Culture, samples were taken at 0h and 2h respectively, and the plate colonies were counted with MRS agar medium for pouring and culture, and the number of viable bacteria was determined and the survival rate was calculated.

[0074] Take 3 mL of Lactobacillus rhamnosus CCFM1131 culture solution by centrifugation at 8000 × g for 2 min to collect the bacterial cells, add 3 mL of pH8.0 artificial simulated intesti...

Embodiment 3

[0078] Example 3: Lactobacillus rhamnosus CCFM1131 has no side effects on KunMing mice

[0079] The Lactobacillus rhamnosus CCFM1131 bacteria were resuspended in 100g / L skim milk solution, and the concentration was 4.0×10 9 CFU / mL bacterial suspension. Twelve healthy male KunMing mice weighing about 24-32 g were selected and divided into CCFM1131 group and control group after one week of acclimatization. The CCFM1131 group was given 0.3 mL of this concentration of bacterial suspension by gavage once a day, and the control group was given the same volume of 100 g / L skim milk solution without Lactobacillus rhamnosus CCFM1131 by gavage for one week, and the death and body weight were recorded.

[0080] The results of these tests are listed in Table 2. These results indicate that feeding concentrations of 1 × 10 9 CFU / Lactobacillus rhamnosus CCFM1131 did not significantly affect the mice, and there was no significant change in body weight and no death phenomenon. The mice show...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a strain of Lactobacillus rhamnosus CCFM1131 for relieving hyperuricemia, which belongs to the technical field of microorganisms. The Lactobacillus rhamnosus CCFM1131 can reduce the level of serum uric acid in mice with hyperuricemia, inhibit the activity of xanthine oxidase (XOD) in serum and liver, and reduce the occurrence of hyperuricemia and gout; the rhamnose Lactobacillus CCFM1131 can down-regulate serum blood glucose, down-regulate serum total triglyceride (TG), down-regulate serum total cholesterol (TC) level and inhibit serum alkaline phosphatase (ALP) activity; in addition, the Lactobacillus rhamnosus CCFM1131 can promote Expression of the ileal uric acid transporter ABCG2. In addition, the Lactobacillus rhamnosus CCFM1131 can tolerate the gastrointestinal tract environment, can be used to prepare functional bacterial agents, foods and medicines for relieving hyperuricemia and gout, and has broad application prospects.

Description

technical field [0001] The invention relates to a strain of Lactobacillus rhamnosus CCFM1131 for relieving hyperuricemia, belonging to the technical field of microorganisms. Background technique [0002] Hyperuricemia (Hyperuricemia, HUA) refers to a disease in which the level of uric acid in the blood exceeds the normal value. In recent years, with the improvement of living standards, the incidence of hyperuricemia is also increasing, and patients with hyperuricemia in my country account for about 13.3% of the total population. Urate stones caused by long-term hyperuricemia can further induce gout. At the same time, hyperuricemia is considered to be a risk factor for cardiovascular and cerebrovascular diseases, chronic kidney disease, and atherosclerosis, which seriously endangers human health. Therefore, the treatment of hyperuricemia has attracted great attention. At present, the main drugs for the treatment of hyperuricemia are allopurinol (xanthine oxidase inhibitor),...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N1/20A61K35/747A61P19/06A61P3/10A61P3/06A61P3/04A23L33/135C12R1/225
CPCA61K35/747A61P19/06A61P3/10A61P3/06A61P3/04A23L33/135A23V2002/00A23V2400/175A23V2200/30
Inventor 赵建新王刚倪彩新王琳琳翟齐啸陆文伟崔树茂杨波毛丙永唐鑫张秋香于雷雷张灏陈卫
Owner 无锡特殊食品与营养健康研究院有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com